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unheated CO2 (U-CO2) in laparoscopic patients. Efficacy data were derived from 
a published randomised controlled trial reporting on the proportion of patients 
with hypothermia, a US database analysis of hypothermia patients for open sur-
gery, and from an unpublished UK NHS before and after study of laparoscopic sur-
gery patients. Other parameter inputs were obtained from published literature. 
Deterministic and probabilistic sensitivity analyses were conducted to assess the 
robustness of results. Scenario analyses were undertaken to explore structural 
uncertainty within the model. Results: The use of WH-CO2 dominated standard 
care, as it was both cost saving and generated greater QALYs, for both open and lapa-
roscopic surgery patients over a one year time horizon. Results varied by the number 
of patients undergoing surgery per humidifier per year. Based on 250 patients using 
the humidifier each year over a five year lifetime of the humidifier, WH-CO2 domi-
nated no insufflation in open surgery patients in 71% of model iterations and domi-
nated U-CO2 in laparoscopic surgery in 98% of model iterations. WH-CO2 remained 
the cost-effective treatment option at a willingness-to-pay threshold of £20,000 per 
QALY throughout all scenario and sensitivity analyses considered, provided 10 or 
more patients used each humidifier over its life span. ConClusions: The analy-
ses conducted suggest that based upon the currently available clinical evidence, 
WH-CO2 is a cost-effective use of resources for patients undergoing either open or 
laparoscopic colorectal surgery within the UK NHS.
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objeCtives: Although several hemostats are available, drawbacks include limita-
tions with efficacy and ease-of-use. Despite their use, uncontrolled bleeding still 
remains common and is associated with important clinical and economic burden. 
A study was conducted to estimate the economic impact of a novel fibrin sealant 
matrix (EVARREST®) versus standard of care (SoC) in problematic severe soft tis-
sue surgical bleeding in the United Kingdom (UK). Methods: An economic model 
quantified 30-day cost impact of EVARREST® from a UK hospital perspective. 
Severe soft tissue bleeding trial resources included quantity of initial treatment, re-
treatment, surgery time, transfusion risk, amount transfused, and hospitalization 
(ICU and ward stay). SoC was composed of Surgicel® (88%) and conventional meth-
ods (e.g., manual compression). The surgical analysis included resources clinically 
related to the significant hemostasis benefit of EVARREST®(i.e., initial and re-
treatment, operating time, transfusion). A hospital analysis included all resources 
collected. Published data on UK costs were applied to resource use. A subgroup 
analysis was conducted for patients meeting coagulopathic criteria based 
on abnormal values for at least one of the trial coagulation parameters col-
lected. Results: The surgical base-case analysis predicted that EVARREST® 
cost was offset by averted resource use with per patient cost impact of £464 
(sensitivity range: -£422 to £1,351) vs. SoC. The hospital analysis predicts fur-
ther resource reduction with EVARREST® leading to cost-savings of £1,006 per 
patient (sensitivity range: -£2,546 to £534). In coagulopathic patients, the results 
dramatically improved, with the surgical and hospital analysis both showing 
cost-savings of £2,526 and £5,720 per patient, with EVARREST®vs. SoC respec-
tively. ConClusions: In problematic bleeding situations, EVARREST® may result 
in important cost savings for hospitals, in addition to meeting an important unmet 
need. This analysis suggests results may depend on bleeding type, with increased 
benefit in challenging (i.e., coagulopathic) bleeding patients. Further study is 
needed to confirm findings.
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objeCtives: The aim of this benchmarking study is to provide a detailed analysis of 
medical devices (MD) price and to identity what drove price dispersion. Methods: 
A large panel of MD level price data was collected in 3 French public healthcare 
institutions and 10 centralized purchasing groups (representing 37% of french public 
hospitals). MD were selected according to the Pareto law (20% of the MD represent 
80% of the expenditure) and expert opinion to ensure that each MD had sufficiently 
large demand. Several factors were considered such as volume purchased, affiliation 
to a purchasing group, procurement procedure and contract start date. Results: 
Finally, 18 MD were retained following up on the provided answers (5 elastic band-
ages, 2 implants, 8 common MD and 3 captive MD). In terms of pricing, results 
between hospitals being close for similar quantifies and none can be defined as 
the benchmark leader. Rebates are a common mechanism and the level of discount 
depends on the MD considered and type of funding (activity based or additional 
payments). Open public tenders are the most commonly procurement procedure 
used, whereas negotiated procedures are more efficient for captive MD. There is 
practically no relationship between volume purchased and purchased prices. MD 
price can change over time and the relevance of the contract start date is con-
firmed: older the contract is, cheaper is the price for some MD, or on the contrary 
for others. ConClusions: There is no connection between catalogue prices and 
purchased prices especially for MD paid by activity based payment (discount rates 
can reach 50% to 90%). As the volume effect has no evident impact on MD discounts, 
the advantage of joining a centralized purchasing group has not been confirmed. 
The crucial factors are mainly the MD considered, the contract start date and the 
procurement procedure.
To further understand this opportunity, this research sought to identify key IC 
practices that would be impacted by MDx testing and could support improved HAI 
outcomes. Methods: Telephone-based primary research was conducted with 
34 hospital quality and IC stakeholders across the US and UK to understand the 
impact of HAIs, current IC practices, quality metrics, outcomes and opportunities 
for MDx. Desk research was carried out to further investigate hospital IC strategies 
and reporting metrics. Results: Hospitals have implemented a variety of strate-
gies aimed at reducing and preventing the incidence of HAIs. Hospitals assess the 
success of their IC strategies by benchmarking their infection rates against national 
or regional reports and measuring compliance with certain IC protocols. There are 
various IC practices that could be impacted by MDx testing such as patient isolation 
and timely administration of targeted antibiotic therapy; however, metrics associ-
ated with these protocols are generally not reported. ConClusions: Primary and 
secondary research findings suggest that compliance with IC protocols is critical to 
improving HAI outcomes. Expanding hospital quality reporting metrics to include 
factors impacted by MDx could support value-based contracting efforts by asso-
ciating testing with improved IC practices, and will ultimately support improved 
HAI outcomes.
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objeCtives: Bioabsorbable drug-eluting sinus implants (BDESI) inserted dur-
ing endoscopic sinus surgery (ESS) have been shown to improve post-operative 
outcomes in the management of refractory chronic rhinosinusitis (CRS) through 
reduced post-operative scarring, inflammation, polyposis and middle turbinate 
lateralization. This study estimated the incremental budgetary impact of incorpo-
rating BDESI in CRS patients undergoing ESS. Methods: A budget impact model 
(following ISPOR’s Good Practice Report) was developed from the perspective of the 
United States payor/self-insured employer. The model was created to be dynamic 
and adaptable to different countries. Estimates of the prevalence of CRS; rates of 
ESS; and effectiveness outcomes; along with direct and indirect costs from CRS 
were obtained from a best-evidence systematic review of the published literature. 
A total population of 1.5 million members was used for the analysis. All cost data 
obtained from the published literature were adjusted to April 2015 US dollars 
using the medical care component of the Consumer Price Index. The comparator 
groups were ESS with BDESI compared to the current clinical peri-/ post-opera-
tive care. Primary outcome was the incremental budget impact reported using 
per-member-per-month (PMPM) costs. Scenario-based, probabilistic, and one-
way sensitivity analyses were performed. Results: For a US payor/self-insured 
employer health plan of 1.5 million members, the incremental PMPM impact of 
BDESI was estimated to range from -$0.009 to $0.09. The results varied based on 
the parameters included in the individual scenario. Sensitivity analyses revealed 
these findings to be robust to specified parameter value ranges. ConClusions: 
Previously published studies have documented the clinical benefits of BDESI. This 
study has demonstrated the use of BDESI during ESS procedures has negligible 
impact on the healthcare budget. Additional research is necessary to determine 
the budget impact for different countries based on the same factors described 
within this analysis.
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objeCtives: To investigate the situation of disposable insulin syringe needles 
re-use in the diabetic patients in Beijing and the safety problems due to re-use 
as well as the extra disease burden. Methods: Use the semi-constructed ques-
tionnaire to investigate how the insulin injection needles were re-used and its 
disease burden on diabetic patients who had been treated by insulin injection 
for at least half a year in 21 hospitals in Beijing. Results: 45.25% of the insulin 
syringe needles were obtained from the pharmacies outside hospitals and the 
average price was 2.76 RMB per piece. Only less than 2% of the diabetics use new 
disposable needle per injection and 30.52% of them only changed their needles 
once per week. The main cause of 84.53% of the diabetics was cost saving. More 
than half of the surveyed diabetics got needle-injection-related hurts such as 
Lipohypertrophy and skin infection. 61.98% got hypoglycemia symptoms in the 
last 3 months. It was estimated that the extra disease burden resulted from the 
safety problems of insulin syringe needles re-use was 458.74 RMB per patient per 
year. ConClusions: At first health education should be enhanced on how to use 
the insulin syringe needles correctly and take it into consideration of bring the 
insulin syringe needles into insurance reimbursement list at appropriate time to 
alleviate the economic burden of the diabetics.
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objeCtives: To determine the cost-effectiveness of local insufflation (via a humidi-
fier) of warm humidified CO2 (WH-CO2) compared with standard care in patients 
undergoing open or laparoscopic colorectal surgery. Methods: A decision-analytic 
model was developed to estimate the costs and quality-adjusted life-years (QALYs) 
associated with open and laparoscopic colorectal surgery from a UK NHS perspec-
tive. WH-CO2 was compared with no insufflation in open surgery patients and with 
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and assumptions were based on the NICE/External Assessment Centre report and 
published literature when possible. Results: Adoption of Sherlock 3CG® TCS was 
predicted to be more or less cost neutral per patient when compared with “blind” 
bedside in both the U.K. (£9.37) and the U.S. ($18.73). Further, Sherlock 3CG® TCS 
was predicted to be cost-saving per patient compared with fluoroscopy in the U.K. 
(-£106.12) or compared with a TLS in the U.S. (-$18.43). These results were robust 
to the majority of sensitivity analyses. ConClusions: This study predicts that 
Sherlock 3CG® TCS is an economically favorable strategy from both U.K. and U.S. 
perspectives and can provide additional patient and healthcare worker benefits. 
Additional analyses in other regions may help to further substantiate these results.
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objeCtives: Although several hemostats are available, drawbacks include limita-
tions with efficacy and ease-of-use. Despite their use, uncontrolled bleeding still 
remains common and is associated with important clinical and economic burden. 
A study was conducted to estimate the economic impact of a novel fibrin sealant 
matrix (EVARREST®) versus standard of care (SoC) in problematic severe soft tissue 
surgical bleeding in Germany. Methods: An economic model quantified 30-day 
cost impact of EVARREST® from a German hospital perspective. Severe soft tis-
sue bleeding trial resources included quantity of initial treatment, re-treatment, 
surgery time, transfusion risk, amount transfused, and hospitalization (including 
ICU and ward stay). SoC was composed of Surgicel® (88%) and conventional meth-
ods (e.g., manual compression). The surgical analysis included resources clinically 
related to the significant hemostasis benefit of EVARREST®vs. SoC (i.e., initial and 
re-treatment, operating time, transfusion). A hospital analysis included all resources 
collected. Published data on German costs were applied to resource use. A sub-
group analysis was conducted for patients meeting coagulopathic criteria based 
on abnormal values for at least one of the trial coagulation parameters collected. 
Value-added tax (19%) was added to product costs. Results: The surgical base-case 
analysis predicted that EVARREST® cost was offset by averted resource use with per 
patient cost impact of € 1,893 vs. SoC. The hospital analysis predicts further resource 
reduction with EVARREST® leading to cost impact of € 608 per patient. In coagulo-
pathic patients, the results dramatically improved, with the surgical and hospital 
analysis both showing cost-savings of € 542 and € 3,275 with EVARREST®vs. SoC 
respectively. ConClusions: In problematic bleeding situations, EVARREST® may 
result in important cost savings for hospitals, in addition to meeting an important 
unmet need. This analysis suggests results may depend on surgical bleeding type, 
with increased benefit seen in challenging (i.e., coagulopathic) bleeding patients. 
Further study is needed to confirm findings.
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objeCtives: Although several hemostats are available, drawbacks include limita-
tions with efficacy and ease-of-use. Despite their use, uncontrolled bleeding still 
remains common and is associated with important clinical and economic burden. 
A study was conducted to estimate the economic impact of a novel fibrin sealant 
matrix (EVARREST®) versus standard of care (SoC) in problematic severe soft tissue 
surgical bleeding in Italy. Methods: An economic model quantified 30-day cost 
impact of EVARREST® from an Italian hospital perspective. Severe soft tissue bleed-
ing trial resources included quantity of initial treatment, re-treatment, surgery time, 
transfusion risk, amount transfused, and hospitalization (including ICU and ward 
stay). SoC was composed of Surgicel® (88%) and conventional methods (e.g., manual 
compression). The surgical analysis included resources clinically related to the sig-
nificant hemostasis benefit of EVARREST®vs. SoC (i.e., initial and re-treatment, 
operating time, transfusion). A hospital analysis included all resources collected. 
Published data on Italian costs were applied to resource use. A subgroup analysis 
was conducted for patients meeting coagulopathic criteria based on abnormal val-
ues for at least one of the trial coagulation parameters collected. Results: The 
surgical base-case analysis predicted that EVARREST® cost was offset by averted 
resource use with per patient cost impact of € 1,016 vs. SoC. The hospital analysis 
predicts further resource reduction with EVARREST® leading to cost-savings of € 708 
per patient. In coagulopathic patients, the results dramatically improved, with the 
surgical and hospital analysis both showing cost-savings of € 2,366 and € 6,128, with 
EVARREST®vs. SoC respectively. ConClusions: In problematic bleeding situations, 
EVARREST® may result in important cost savings for hospitals, in addition to meet-
ing an important unmet need. This analysis suggests results may depend on surgi-
cal bleeding type, with increased benefit seen in challenging (i.e., coagulopathic) 
bleeding patients. Further study is needed to confirm findings.
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objeCtives: economic analysis of telemedical technologies application for regular 
medical examination among the adult population living far from hospitals in the 
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objeCtives: Presently, there is a disparity between the purchasing power of vari-
ous hospital institutions within Germany. Large institutions, those within hospital 
networks, and those with group purchasing organization (GPO) memberships can 
leverage their influence to secure favorable prices for medical devices and consuma-
bles. Other institutions, however, are not able to leverage the same purchasing power, 
resulting in higher prices and financial inefficiencies. The objective of this work was 
to measure the financial impact to a broad spectrum of hospitals using real-world 
German hospital purchasing and consumption data. Methods: GfK Hospital Panel, a 
proprietary database for German hospital medical devices and consumables purchas-
ing and consumption was evaluated. Wound care purchasing data was evaluated to 
see similarities and differences in purchasing volume, acquisition cost, and product 
utilization. Products used to promote infection control and healing in post-surgical 
sites were prioritized. Results: The hospital purchasing and consumption data 
identified how specific products were used within and across hospitals. Differences 
in consumption by specialty department/units show how purchasing decisions are 
being concentrated in different settings. Hospitals with greater buying power and 
those with access to group purchasing organizations paid less per unit price than 
other hospitals, however the mix of products used varied by setting. Advanced wound 
care products had the greatest variability in usage among hospitals within the sam-
ple. ConClusions: Databases that provide detailed hospital purchasing data provide 
greater transparency to both hospitals and innovators on purchasing, pricing, and 
utilization trends. Smaller hospitals and those independently negotiating purchasing 
contracts can leverage this information to understand practice in other hospital set-
tings as they make decisions for their own. These data are likely to have a significant 
impact in rationalizing expenditures across the German Healthcare System, providing 
transparency to help hospitals make better purchasing decisions.
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objeCtives: Intraoperative watertight dural closure is critical as CSF leakage can 
lead to an increased risk of costly clinical consequences (e.g., wound infection, men-
ingitis). Although there are several fibrin sealants available, not all are indicated 
for sealing dura mater. An economic analysis compared a fibrin sealant (EVICEL® 
Solutions for Sealant) with standard of care (SoC) for sutured dural closure in cranial 
surgery in the United Kingdom (UK). Methods: The economic analysis quantified 
the 30-day cost impact of EVICEL® from a U.K. hospital perspective based on a surgical 
approach using clinical trial data. SoC was composed of sutures in addition to rescue 
therapy for the majority of the population. Trial-reported resources used included 
the quantity of initial treatment, adjunctive and rescue therapy product utilization, 
operating room (OR) time, hospitalization duration, and risk of dural-related adverse 
events. Only SoC treatment successes were allowed to receive additional adjunctive 
therapies to ensure durability of closure; however, treatment failures in both Evicel® 
and SoC could receive rescue therapies. Adjunctive therapies consisted of sutures, 
collagen, and haemostats (not fibrin sealants); where as rescue therapies consisted 
of various glues, haemostats and autologous dural patches. Published data on U.K. 
costs were applied to resource use and several one-way sensitivity analyses were 
conducted. Results: The analysis estimated that resource savings with EVICEL® 
completely offset its acquisition cost and resulted in cost savings of £207 per patient 
(sensitivity range: -£727.02 to £313.40) compared with SoC. Results remained robust 
to the majority of sensitivity analyses; however were most sensitive to assumptions 
regarding OR time and hospitalization duration. ConClusions: The use of EVICEL® 
for suture line dural closure may result in important cost savings for hospitals, partly 
driven by the reduced need for other adjunctive and rescue therapies. Further studies 
in larger populations may help to substantiate findings.
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objeCtives: The Sherlock 3CG® Tip Confirmation System (TCS) is designed to con-
firm the correct tip placement of a peripherally inserted central catheter (PICC) by 
using magnetic real-time tracking and electrocardiographic catheter tip confirma-
tion. The National Institute for Health and Care Excellence (NICE) recommended 
the adoption of Sherlock 3CG® TCS based on modelled health economic benefits 
in the United Kingdom (U.K.). The objective of this study was to develop a United 
States (U.S.) model for Sherlock 3CG® TCS and compare these results to the U.K. 
analyses. Methods: Sherlock 3CG® TCS was compared with “blind” beside PICC 
placement, as well as region-specific PICC placement methods (i.e., fluoroscopy in 
the U.K. and tip location system (TLS) in the U.S.). Clinical and economic outcomes 
were assessed per patient over the duration of a successful PICC insertion procedure. 
All eligible patients with an identifiable P-wave in their ECG rhythm were assumed 
to switch to Sherlock 3CG® TCS and did not require confirmatory chest x-rays. PICC 
placement success rates, as well as region-specific costs for capital, maintenance, 
nurse training, consumable materials, and chest x-rays were included. Parameters 
